Stock Yards Bank & Trust Co. Has $2.34 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Stock Yards Bank & Trust Co. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 9.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 92,503 shares of the biopharmaceutical company’s stock after selling 9,878 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Pfizer were worth $2,344,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Down 1.3%

Shares of PFE opened at $24.51 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market cap of $139.35 billion, a P/E ratio of 17.38, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a 50 day simple moving average of $23.06 and a two-hundred day simple moving average of $24.96.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business posted $0.82 earnings per share. The company’s quarterly revenue was down 7.8% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.02%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.